Consequently, Leo may function as a crucial pharmaceutical agent inhibiting EMT by targeting FUT4 in lung carcinoma, possessing the potential to impede tumor proliferation by suppressing EGFR and its downstream signaling pathways. Here, FUT4 is linked to lung carcinoma.